Laurus Labs Limited — Others, 27-01-2025: News Verification

Laurus Labs has issued a clarification regarding concerns raised by a media report on potential funding freezes by the US government for AIDS relief programs. The company asserts that the ARV medicine market, valued at approximately US$ 1.5 billion, accounts for only 10% of total annual HIV financing. It believes that any funding challenges will not significantly impact medication procurement. Moreover, the company remains optimistic about its operations, noting a positive development with the US rejoining WHO. This announcement may foster a positive outlook among investors, as it mitigates fears over funding disruptions.